Dalfampridine (4-Aminopyridine)

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Substrate of
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

North America

USA: Ampyra.

Drug combinations


Dalfampridine: C~5~H~6~N~2~. Mw: 94.1. (1) 4-aminopyridine; (2) Avitrol; (3) γ-Aminopyridine. CAS 504-24-5.

Pharmacologic Category

Other Miscellaneous Therapeutic Agents; Potassium Channel Blocker. (ATC-Code: N07XX07).

Mechanism of action

Has not been fully elucidated. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

Therapeutic use

Indicated to improve walking in multiple sclerosis.

Pregnancy and lactiation implications

Based on animal data, may cause fetal harm. Discontinue drug or nursing taking into consideration importance of drug to mother.

Unlabeled use


History of seizure. Moderate or severe renal impairment.

Warnings and precautions

May cause dose-dependent seizures; contraindicated in prior history of seizure; use should be discontinued if seizure occurs. Contraindicated in moderate or severe renal impairment (CrCl ≤50 mL/min); the risk of seizures in mild renal impairment (CrCl: 51-80 mL/min) is unknown. Should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same. Urinary tract infections were reported more frequently in patients receiving this treatment compared to placebo.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart